Hyperlipidemia is an increase in the plasma lipids like triglycerides, cholesterol, phospholipids and low density lipoproteins (LDL) with reduction in high density lipoproteins (HDL). Elevated LDL meanwhile is accepted as the leading factor which causes atherosclerosis from decades. Therapeutic control beginning with statins and fibrates has kept it under the bar to some extent but myalgia and other side effects are worrisome due to them. Many new drug targets to treat hyperlipidemia are available now. The review focuses on new strategy as well as new lipid lowering agents available for this major risk factor for cardiovascular diseases.
Impact Factor
2022: 6.012
This work is licensed under a